Head-to-head · Cost-Efficiency Index
Direct Meds vs MyFastRx
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Direct Meds
Needle-averse shoppers who want a sublingual route on either molecule and will pay above the going rate for it, having accepted a three-month supply as the smallest unit sold.
Visit Direct MedsMyFastRx
Cost-first shoppers who want cash-pay shoppers comfortable prepaying several months upfront to reach the lowest per-month compounded-GLP-1 rate on the market.
Visit MyFastRxThe verdict
MyFastRx takes it, leading the Cost-Efficiency Index 73 to 71. MyFastRx is a cash-pay compounded-GLP-1 platform with a full published price ladder: a $139/mo semaglutide and $199/mo tirzepatide standing month-to-month rate, a discounted first month with a promo code. Direct Meds still earns a C — Needle-averse shoppers who want a sublingual route on either molecule and will pay above the going rate for it, having accepted a three-month supply as the smallest unit sold.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs MyFastRx.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Direct Meds | MyFastRx |
|---|---|---|
| Cost-Efficiency Index | 71/100 | 73/100 |
| Semaglutide / mo | $249/mo (sublingual, 90-day supply billed monthly) | $139/mo (all doses, promotional rate, compounded) |
| Tirzepatide / mo | $299/mo (sublingual, 90-day supply billed monthly) | $199/mo (all doses, promotional rate, compounded) |
| Semaglutide / yr (modeled) | $2,988 | $1,668 |
| Tirzepatide / yr (modeled) | $3,588 | $2,388 |
| Coverage | Not disclosed | All 50 states |
| Oral / sublingual | Yes | No |
| Brand-name access | Compounded only | Compounded only |
| Rank here | #64 | #68 |
Direct Meds
71/100Where the value is
- Sublingual AND injection on BOTH molecules — four GLP-1 SKUs, the widest formulation range of any provider in this ranking
- Every price is published per SKU in a public shop, with no quiz, intake or email capture in front of it
- Each product page prints a per-day equivalent beside the monthly rate ($8.03/day at $249), which is unusually concrete for this category
The tradeoffs
- $249/mo sublingual is well above this ranking's ~$144 median, and the injection route is $297 — the cheapest thing here is dearer than most rows' headline price
- The only purchasable option on every product page is a 90-DAY SUPPLY billed monthly, so three months is the smallest unit sold — there is no month-to-month rate to compare against the rows beside it
Regulatory note: the FDA issued a warning letter to directmeds.com, Inc. dba DirectMeds in September 2025. We still list and link to Direct Meds; you should know the letter is on the public record before you decide.
MyFastRx
73/100Where the value is
- Publishes a full, specific price ladder (1/3/6/12-month) rather than a single vague 'starting at' figure
- LegitScript certified
- Flat pricing across all doses — no dosage upcharges as you titrate
The tradeoffs
- The true no-commitment monthly rate ($139 sema / $199 tirz) is meaningfully higher than the deep prepay-bundle rates the marketing emphasizes ($79-99 / $124-166) — those low numbers require paying for 3, 6, or 12 months upfront
- The lowest first-month price ($69 / $129) requires entering a promo code and applies to one month only
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.